AUTHORS: Maas MO, Forrer F, Panje CM, Blautzik J, Brühlmeier M, Engel-Bizik I, Giovanella L, Haldemann A, Kamel ME, Kneifel S, Rottenburger C, Schaefer N, Walter MA, Weidner S, Putora PM

European Journal of Nuclear Medicine and Molecular Imaging, 47(3): 554-560, March 2020

ABSTRACT

Background

The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.

Methods

We analyzed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies.

Results and Conclusion

We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centers.

Download PDF

 

BibTex

Module: